featured
-
Roche Phase II GENERATION HD2 study underway
6 min read
Roche released a community letter in early 2023, to share that their Phase II clinical trial to study the huntingtin-lowering drug, tominersen, is now underway. In this article, we summarise the latest news about this huntingtin-lowering drug.
-
Disappointing news from Novartis about branaplam and the VIBRANT-HD trial
8 min read
Novartis have announced that they are ending development of the drug branaplam in Huntington’s disease. Here, we review this latest news and its impact on the HD community.
-
uniQure gets the green light to resume testing HD gene therapy
4 min read
Following a 3-month pause in enrollment due to concerns about side effects, uniQure shared the good news that their trial of the HD gene therapy AMT-130 will continue as planned, with new safety measures in place.
By Dr Leora Fox -
Update on the PTC Therapeutics PIVOT-HD Trial
5 min read
Last week, PTC Therapeutics released a statement sharing that recruitment of participants into the US arm of the PIVOT-HD trial has been paused. In this article, we will lay out exactly what is known and what this announcement means.
-
Forward momentum for Roche and Wave in latest news about huntingtin-lowering trials
11 min read
Two companies developing medicines for Huntington’s disease announced news about their huntingtin-lowering drugs. Let’s talk about the history and the caveats surrounding these hopeful pieces of news.
-
Focusing in on fibrils; scientists give us a glimpse of huntingtin protein clumps
7 min read
Scientists have used powerful microscopes to look at sticky fragments of the Huntington’s disease protein, shedding light on these structures which are thought to drive the disease
-
Hereditary Disease Foundation (HDF) conference 2022 – Day 4
7 min read
Read updates from clinical trials and scientific research on Huntington’s disease from Day 4 of the 2022 HDF Milton Wexler Biennial Symposium #HDF2022
-
Hereditary Disease Foundation (HDF) conference 2022 – Day 3
11 min read
Read updates from clinical trials and scientific research on Huntington’s disease from Day 3 of the 2022 HDF Milton Wexler Biennial Symposium #HDF2022
-
Serious side effects reported for some people treated with the huntingtin-lowering drug AMT-130, currently in clinical trials
8 min read
After receiving a high dose of uniQure’s gene therapy for Huntington’s disease, a few patients experienced serious side effects, but are now recovering. HDBuzz explores what this means for the experimental huntingtin-lowering drug, AMT-130.
-
Sad news from Novartis: dosing suspended in VIBRANT-HD trial of branaplam
7 min read
HDBuzz is saddened to share the news that the VIBRANT-HD trial of the oral huntingtin-lowering drug, branaplam, has been temporarily suspended for the safety of participants.
By Dr Leora Fox